$GH

Krognes Steve E. sold $1.2M of GH

Krognes Steve E. sold 9,294 shares of Guardant Health, Inc. (GH) at $132.51 ($1.23M total) on 2026-06-04.

Original reporting
SEC EDGAR · Krognes Steve E.
Published Jun 5, 2026, 11:50 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 5, 2026, 11:52 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$GH
Neutral
medium confidence
Mentioned
$GH
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$GHNeutralLow
01

Why it matters

The key trading angle is whether the sale is interpreted as a bearish signal given it was not under a pre-arranged 10b5-1 plan; however, insider sales alone rarely drive sustained repricing without accompanying fundamental news.

02

Market read

A single director sale worth ~$1.23M may slightly pressure sentiment, but there is no new operational/financial catalyst in the filing.

03

What to watch

The article lacks context on prior insider activity frequency, option exercises, tax events, and whether the director retains meaningful exposure post-sale.

Relevance 6/10Novelty 6/10Timing: After SEC Form 4 filing (filed 2026-06-05) for a 2026-06-04 sale

Background

This is an SEC Form 4 insider transaction disclosure for Guardant Health, Inc. (GH).

Company-level read

Ticker impact

$GHNeutralMedium confidence
Context

Guardant Health director Steve E. Krognes sold 9,294 shares in an open-market transaction worth about $1.23M, disclosed via SEC Form 4.

Expected impact

Low near-term impact; any effect is likely sentiment-driven and short-lived.

Evidence & confidence

The filing provides a specific sale price/size and confirms it was not under a pre-arranged 10b5-1 plan, which can increase interpretive sensitivity, but it does not include new company fundamentals.

Market effects

Minimal; this is company-specific insider activity with no stated sector-wide development.

None indicated.

None indicated.

Counterpoint

Non-10b5-1 sales can be routine liquidity/portfolio rebalancing and may not reflect negative expectations.

Key entities

  • Guardant Health, Inc.

    Issuer of the SEC Form 4 insider transaction; director sold 9,294 shares at ~$132.51.

  • Steve E. Krognes

    Director who executed the open-market sale; holdings after transaction were 10,222 shares.

Related articles

$GHHighAI 9/10

Guardant Health (GH) Q2 2026 Earnings Call Transcript

Guardant Health (GH) reported Q2 2026 revenue of $335 million, up 44% year over year, driven by Oncology, Biopharma & Data, and Screening. Oncology revenue was $219.1 million, up 38%, with test volumes around 104,000. Full-year guidance: revenue $1.34 to $1.36 billion and free cash flow burn $195 to $205 million.

$GHMedAI 8/10

New blood test to detect colon cancer clears FDA approval

The FDA approved Freenome’s SimpleScreen blood test for colorectal cancer screening in adults aged 45+ at average risk. In a study of 48,000+ people, it detected about 80% of colorectal cancers and correctly tested negative in about 90% without cancer or advanced precancer. It is expected to launch this fall with Abbott. Guardant Health’s Shield was approved in 2024.

$GHMedAI 8/10

Guardant Health, Inc. Q2 2026 Earnings Call Summary

Guardant Health reported 44% YoY Q2 2026 revenue growth, citing strong Oncology and Screening performance. It raised full-year 2026 revenue guidance to $1.34B-$1.36B and expects lower Shield cost per test. FDA approval of Guardant360 Liquid CDx and UnitedHealth coverage for Shield from Aug. 1, 2026 are key catalysts.

$GHHighAI 9/10

Why is Guardant Health stock surging today?

Nasdaq sees best day in over a month as Microsoft breathes life back into AI trade Investing.com -- Guardant Health stock surged 8.8% in after-hours trading after the Palo Alto-based liquid biopsy pioneer reported second-quarter 2026 results that significantly exceeded revenue expectations, with sales reaching $335 million — a 44% year-over-year increase that beat the Wall Street consensus of roughly $314 million by approximately 6.4%.